Bristol-Myers seeks approval in Japan for Hepatitis C combo

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) has filed for Japanese authorization of its daclatasvir and asunaprevir combination treatment for Hepatitis C.

The move comes after the combo cured 84.7% of 222 patients after 24 weeks in a Phase III trial.

In early 2014, Bristol wants to test the drugs in a combination with another medicine, BMS791325, over a 12-week period.

Bristol-Myers submission is the first one that doesn't include the standard treatments interferon and ribavirin, which are difficult to tolerate. (PR)